Mark Lappe, New Inhibrx CEO
Sanofi wades into AATD in $1.7B bid for Inhibrx's rare disease drug
In its first M&A move of 2024, Sanofi is grabbing what it sees as a potential best-in-class therapy for its rare disease pipeline by snapping …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
